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Background: The study examined the Lp-PLA2 activity at the patients presented to the emergency
department with acute coronary syndrome (ACS) or acute ischemic stroke (AIS), as well as its diagnostic
value.
Methods: The prospective study included consecutive male and female patients aged >18 years that
presented to the our emergency department with ACS or AIS between November 2009 and January 2010.
Blood samples were obtained immediately following diagnosis in the ACS and AIS groups. The diagnostic
value of Lp-PLA2 was determined based on receiver operating characteristic curves, sensitivity, speci-
ﬁcity, predictive values, likelihood ratios and accuracy rates.
Results: In all, 34 ACS and 32 AIS patients were included in the study, and the control group included 35
patients. Lp-PLA2 enzyme activity was signiﬁcantly lower in the ACS and AIS groups than in the control
group (26.7 ± 13.8, 31.4 ± 13.6, and 41.4 ± 8.1 nmol min1$mL1, respectively; p < 0.0001, p ¼ 0.022). In
the ACS group the area under the curve (AUC) was 0.825 (95%CI: 0.722e0.929), sensitivity was 71% for an
optimal Lp-PLA2 cut-off value of 31.4 nmol min1$mL1, and speciﬁcity was 91%, whereas in the AIS
group the AUC was 0.768 (95%CI: 0.652e0.884), sensitivity was 75% for an optimal Lp-PLA2 cut-off value
of 38.1 nmol min1$mL1, and speciﬁcity was 74%.
Conclusions: Lp-PLA2 enzyme activity was signiﬁcantly lower during the early stage of both ACS and AIS.
The obtained statistic data suggest that low Lp-PLA2 enzyme activity can be used for diagnostic purposes.
Copyright © 2016 The Emergency Medicine Association of Turkey. Production and hosting by Elsevier
B.V. on behalf of the Owner. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The lipoprotein-associated phospholipase-A2 (Lp-PLA2), which
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chemic stroke, Turkish JoAH). Lp-PLA2 is a member of the phospholipase A2 super family. It is
stated that Lp-PLA2 is produced by myeloid-originated inﬂamma-
tory cells, is associated with atherogenic lipoproteins in the circu-
lation, and is highly expressed in lesion regions.1
Lp-PLA2 hydrolyzes oxidized phospholipids, which form pro-
inﬂammatory products that contribute to endothelial dysfunction,
plaque inﬂammation and formation of the necrotic core in the
plaque. Moreover, it is thought that Lp-PLA2 constitutes a link be-
tween oxidative modiﬁcation of LDL (Low Density Lipoprotein) and
increased inﬂammatory response in the arterial intima.2 Addi-
tionally; Lp-PLA2 exhibits pro-inﬂammatory characteristics. It hy-
drolyzes oxidized phospholipids into lysophosphatidylcholine and
free fatty acids. The atherogenic potential of LDL is related to thisand hosting by Elsevier B.V. on behalf of the Owner. This is an open access article
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In the last decade, many studies have examined the effects of Lp-
PLA2 on atherosclerosis. The purpose of these studies was to
determine the utility of Lp-PLA2 in risk prediction or risk classiﬁ-
cation of cardiovascular diseases (CVDs).4 To the best of our
knowledge the literature contains few studies on the diagnostic
use of the Lp-PLA2 level in patients with acute coronary syndrome
(ACS) or acute ischemic stroke (AIS).5,6 As such, the present study
aimed to examine the Lp-PLA2 activity and its diagnostic potential
in early period ACS and AIS patients.
2. Methods
2.1. Patients and process
The prospective study included consecutive male and female
patients aged >18 years that presented to our emergency depart-
ment with ACS or AIS between November 2009 and January
2010.The control group included consecutively patients without a
history of or current thromboembolic events that presented to the
emergency department with other complaints.The number of pa-
tients in each group was determined as about 30 considering the
ﬁnancial support of the study. The patients under 18 years were not
included in the study in accordance with ethical rules. The patients
who had the following were also excluded from the study due to
their potential to affect lipoprotein metabolism, acute inﬂamma-
tory response, cardiac troponin and CK-MB (Kreatin KinazeMB)
levels and thereby the results of the study 7e10: accompanying
serious trauma, acute or chronic liver or renal failure, traumatic
venous occlusion, hemorrhagic diathesis or coagulation disorders,
hematologic malignancies, acute or chronic inﬂammatory disease,
use of anti-aggregates, anticoagulants, anti-hyperlipidemia, or anti-
inﬂammatory agents, and pregnancy. All ACS patients were exam-
ined by a cardiologist, whereas all AIS patients were examined by a
neurologist and a neuroradiologist. In the diagnosis of ACS, the
criteria which were published currently in guidelines were
considered.11
For AIS group, all patients who had acute focal or systemic
stroke signs (eg. alteration in consciousness, weakness of extrem-
ities, etc.) were determined with their ﬁrst evaluation and blood
sampling was taken. After the diagnosis of AIS was conﬁrmed with
computed tomography (CT) and/or diffusion weighted magnetic
resonance imaging (DWI), those patients were included into AIS
group.
Patients were enrolled in the study following veriﬁcation of
their diagnosis via appropriate diagnostic tests and provision of
written informed consent. Blood samples were obtained from these
patients for Lp-pLA2, Crp (C reaktif protein), Tn-I (Troponin I) and
CK-MB analyses, and the Lp-pLA2 levels were compared to the
other parameters. The sample drawn period was deﬁned as the
time from the onset of symptoms to blood drawn and it was
categorized as 6 h, 6<<12 h, and 12 h in the ACS and AIS
groups. A possible difference between the sample drawn periods as
well as Lp-PLA2 levels both within and between the ACS and AIS
groups was investigated. The study protocol adhered to the Hel-
sinki Declaration and was approved by the Ethics Committee of
Selcuk University Meram Medicine School. The study was sup-
ported by the Scientiﬁc Research Projects Coordination Ofﬁce of
Selcuk University.
2.2. Sample drawn
Each patient provided 10 cc of venous blood, which was
collected into test tubes containing EDTA (Etilendiamin tetraasetik
asit). After plasma was separated from the obtained samples viaPlease cite this article in press as: Kocak S, et al., Lipoprotein-associated p
acute coronary syndrome and acute ischemic stroke, Turkish Jo
j.tjem.2016.10.001cold centrifugation at 4 C and 700e1000 g for 10 min, the plasma
samples were placed in Eppendorf tubes and preserved at 80 C
until used.
2.3. Biochemical method
A commercially available colorimetric assay (PAF Acetyl hydro-
lase Assay Kit, Catalogue no. 760901, Cayman Chemical Company,
USA) was used to measure the plasma PAF-AH. This method uses 2-
thio PAF to serve as a substrate for all PAF-AHs. Free thiols emerging
from hydrolysis of the acetyl thioester bond in the sn-2 position are
identiﬁed using 5,50 -dithio-bis-(2-nitrobenzoic acid) (DTNB; Ell-
man's reagent). All laboratory personnel were blinded to the study
and control group patients' clinical data and outcomes. Electro-
chemiluminesans assay (Roche Hitachi, Cobas e 411, Roche Diag-
nostic Turkey Company) was used to measure CK-MB and Troponın
I. Nephalometrically assay (BN2 SIEMENS) was used to measure
CRP.
2.4. Statistical analysis
Study data were analyzed using Statistical Package for the Social
Sciences (SPSS) forWindows v.19.0. Parametric testing was used for
data with normal distribution (according to the Lilliefors test) and
non-parametric testing was used for data not normally distributed.
The chi-square test was used to evaluate the distribution of gender,
hypertension (HT), diabetes mellitus (DM), coronary heart disease
(CHD), hyperlipidemia (HL), and smoking, according to group. One-
way analysis of variance (ANOVA) was used to compare patient age
and Lp-PLA2 activity between groups. When ANOVA test results
were signiﬁcant Tukey's HSD post hoc test was used. Time is used as
covariant in order to control the effect.
The relationship between the sample drawn period and LP-PLA2
activity within groups was assessed using the Kruskal-Wallis test
and between groups using Pearson's correlation analysis. The cor-
relation of level of Lp-PLA2 and other biochemical parameters be-
tween groups were performed by Spearman's Test and its' accuracy
was tested by Scatter-Dot Graphs. The level of statistical signiﬁ-
cance was set at p < 0.05. ROC (Receiver Operating Characteristic)
curves were used to determine the diagnostic properties of speciﬁc
Lp-PLA2 activity values in the ACS and AIS groups, as compared to
the control group. In addition to the area under the curve (AUC), the
sensitivity, speciﬁcity, positive predictive value (PPV), negative
predictive value (NPV), positive and negative likelihood ratios (LR),
accuracy rate (AR), odd ratio and conﬁdence interval (CI) were
determined. In addition to cut-off values in which sensitivity and
speciﬁcity were the highest in total, calculations alsoweremade for
probable cut-off values in which sensitivity or speciﬁcity would be
higher. In ACS group, the second ROC curve was performed with
reference to Tn-I and the diagnostic potential was calculated.
3. Results
In all, 34 ACS and 32 AIS patients, and 35 control patients were
enrolled in the study. Mean age of the ACS patients was 62.2 ± 12.0
years (range 23e83), 28 (82.4%) of them were male; mean age of
the AIS patients was 64.7 ± 13.9 years (range 40e91), 18 (56.3%) of
them were male, and mean age of the control patients was
51.5 ± 17.2 years (range 20e90), 17 (48.6%) of them were male
(Table 1). Mean age in the AIS group was signiﬁcantly higher than
that in the control group (p ¼ 0.007). Similarly, male patients were
signiﬁcantly more prevalent than that in the other groups
(p ¼ 0.003). A correlation was not detected between Lp-PLA2 levels
and age, gender of the groups (p ¼ 0.72 ve p ¼ 0.91 respectively).
Mean sample drawn period in the ACS group was 11.2 ± 17.0 h,hospholipase-A2 activity and its diagnostic potential in patients with
urnal of Emergency Medicine (2016), http://dx.doi.org/10.1016/
Table 1
Demographic characteristics and medical history of the groups.
ACS AIS Control p
n 34 32 35
Sex (men) (%) 82.4 56.3 48.6 0.003
Age (mean ± SD) 62.2 ± 12.0 64.7 ± 13.9 51.5 ± 17.2 0.007
HT (%) 16 (47.0) 23 (71.9) 15 (42.9) NS
DM (%) 11 (32.3) 12 (37.5) 7 (20.0) NS
CHD (%) 14 (41.2) 12 (37.5) e 0.05
HL (%) 13 (38.2) 11 (34.4) 3 (8.6) 0.04
Smoking (current) 9 (26.5) 11 (34.4) 11 (31.4) NS
ACS: Acute coronary syndrome, AIS: Acute ischemic stroke, HT: Hypertension, DM:
Diabetes mellitus, CHD: Coronary heart disease, HL: Hyperlipidemia, NS: No
signiﬁcance.
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Fig. 1. ROC curve for ACS and AIS patients in the Lp-PLA2 values.
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ation between the sample drawn period and Lp-PLA2 activity in the
ACS and AIS groups, both intra-group (p ¼ 0.38 and p ¼ 0.86,
respectively) and between the two groups (p ¼ 0.33). There was a
signiﬁcant statistical difference between ACS and control group in
terms of TnI and CK-MB levels (p ¼ 0.005, p < 0.0001 respectively).
The level of CRP was higher in both ACS and AIS group when
compared with control group, which had statistical signiﬁcance
(p ¼ 0.02, p < 0.0001 respectively). But there was no signiﬁcant
difference found between ACS and AIS groups in terms of CRP levels
(p ¼ 0.26).
Lp-PLA2 enzyme activity was signiﬁcantly lower in the ACS and
AIS groups than in the control group (p < 0.0001 and p ¼ 0.022,
respectively) (Table 2); however, it did not differ signiﬁcantly be-
tween the ACS and AIS groups (p ¼ 0.67). Although a signiﬁcant
correlation was found between levels of TnI and CK-MB in the ACS
group (r ¼ 89, p < 0.0001), there was not any correlation between
TnI and Lp-PLA2, CK-MB and Lp-PLA2. Also, no signiﬁcant correla-
tion was found between levels of CRP and Lp-PLA2 in both the ACS
and AIS groups.
Separate ROC curveswere plotted and the AUCwas estimated for
each group in order to determine the capability of the serum Lp-
PLA2 enzyme activity to detect the acute event (Fig. 1). In the ACS
group the AUC was 0.825 (95% CI: 0.722e0.929) and the standard
error was 0.053. Accordingly, the optimal Lp-PLA2 cut-off value of
31.4 nmolmin1mL1 had a sensitivity of 71%, speciﬁcity of 91% and
odd ratio 25.60 (5.56e136.21). In the AIS group the AUC was 0.768
(95% CI: 0.652e0.884) and the standard error was 0.059. Accord-
ingly, the optimal Lp-PLA2 cut-off value of 38.1 nmol min1$mL1
had a sensitivity of 75%, speciﬁcity of 74% and odd ratio 8.67
(2.55e30.92) (Table 3). When ROC analysis was performed with
reference to TnI, AUC ¼ 0,798 (CI%95, 0,688e0,907) and standard
error of 0,056 were found. So that, when the cut-off point was
accepted as 37.7 nmol/min/ml that was optimum Lp-PLA2 cut-off
point, sensitivity was 76% and speciﬁcity was 72% (Table 4).
4. Discussion
In our study, Lp-PLA2 enzyme activity was signiﬁcantly lower inTable 2
Biochemical measurement values of the groups.
ACS
Sample draw time (h)
(Median) 5.6
(Range) 1e86
Tn I (ng/mL) (mean ± SD) 14.8 ± 29.0
CK-MB (ng/mL) (mean ± SD) 84.9 ± 105.3
CRP (mg/L) (mean ± SD) 22.0 ± 36.2
LP-PLA2 enzym activity (nmol/min/mL) (mean ± SD) 26.7 ± 13.8
NA: Not available, NS: No signiﬁcance.
Please cite this article in press as: Kocak S, et al., Lipoprotein-associated p
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the control group.
It was reported that Lp-PLA2 levels in women during the pre-
menopausal period are generally lower than in men and that the
Lp-PLA2 level increases with age.12 In the present studymean age in
the AIS group was higher than that in the control group, and the
male ratio was higher in the ACS group; therefore, we think that a
low Lp-PLA2 level becomemore signiﬁcant in a population inwhich
age and the male ratio are higher than in a control group. The
literature contains few studies in which the Lp-PLA2 level was
measured following acute events. In a study that included 12 male
patients admitted to hospital with Acute Myocardial Infarction
(AMI), the PAF-AH activity level decreased on days 2 and 7 of
hospitalization.13 Another study reported that the PAF-AH level in
blood samples taken from 18 patients with AMI 6 h after presen-
tation was signiﬁcantly lower than that in the control group.14
Elkind et al. measured both Lp-PLA2 mass and activity before
and after acute events in 37 patients (20 with myocardial infarction
(MI) and 17 with stroke).15 The researchers reported that Lp-PLA2
mass and activity were signiﬁcantly lower after acute events both
in MI and stroke patients than before. They stated that the median
sample drawn period was 5 days (range 2e40 days). The median
sample drawn period in the present study was approximately 6 h
and the maximum was 3.5 days. The researchers argued that Lp-
PLA2 level may have decreased in accordancewith a decrease in LDL
levels after MI due to co-localization of Lp-PLA2 and LDL or that
acute phase proteins, such as albumin and ﬁbrinogen, may have
affected the binding and activity capacity of Lp-PLA2.
Jabor et al. found Lp-PLA2 mass levels higher in ACS patients
who admit within 48 h following symptom onset compared to theAIS Control p
7.2 NA NS
1.5e28
NA 0.02 ± 0.02 0.005
NA 2.4 ± 3.0 <0.0001
31.8 ± 25.0 5.3 ± 2.9 0.02
31.4 ± 13.6 41.4 ± 8.1 <0.0001
hospholipase-A2 activity and its diagnostic potential in patients with
urnal of Emergency Medicine (2016), http://dx.doi.org/10.1016/
Table 3
Diagnostic performance of Lp-PLA2 enzyme activity according to different cut-points in the ACS and AIS patients.
ACS AIS
AUC
SE
CI 95%
0,825
0.053
0,722e0,929
0,768
0.059
0,652e0,884
Cut-offa (nmol/ml/min) 26.1 31.4 41.1 35.5 38.1 41.9
Sensitivity %
CI 95%
50
34e66
71
54e84
88
74e96
59
42e75
75
58e87
88
73e96
Speciﬁcity %
CI 95%
97
87e100
91
79e98
49
33e65
80
65e91
74
55e84
46
30e62
PPV %
CI 95%
94
77e99
89
73e98
63
48e75
73
54e87
71
54e84
60
45e73
NPV %
CI 95%
67
53e78
76
62e87
81
61e93
68
53e81
76
59e88
80
59e93
(þ)LR
CI 95%
17.50
2.89e351.74
8.24
2.89e32.17
1.72
1.20e2.18
2.97
1.41e6.79
2.92
1.60e5.32
1.61
1.13e2.04
()LR
CI 95%
0.52
0.47e0.71
0.32
0.24e0.52
0.24
0.07e0.66
0.51
0.34e0.80
0.34
0.17e0.63
0.27
0.08e0.75
AR %
CI 95%
74
63e83
81
71e89
68
57e78
70
59e80
73
62e83
66
54e76
ACS: Acute coronary syndrome, AIS: Acute ischemic stroke, AUC: Area under curve, SE: Standard error, CI: Conﬁdence interval, PPV: Positive predictive value, NPV: Negative
predictive value, LR: Likelihood ratio, AR: Accuracy rate.
a The analyzes based on the cut off with high sensitivity appear on the right side of the middle column and those based on cut off with high speciﬁcity appear on the left side
of the middle column. Middle column represents the optimum cut off values.
S. Kocak et al. / Turkish Journal of Emergency Medicine xxx (2016) 1e54recovery patients 12weeks later.6 Lp-PLA2 levels were found higher
in patients with AIS in the study of Kara et al. An association was
found between Lp-PLA2 levels and stroke severity and infarction
size. The authors state that they included the acute stroke patients
who admit to emergency department within the ﬁrst 24 h
following symptom onset however they do not provide a detailed
information about the time to obtain blood samples.5 Tai et al. re-
ported that Lp-PLA2 mass and activity do not show a signiﬁcant
change in patients with acute cerebral ischemia. However this
study is different from ours as almost half of the patients have TIA
and median time to obtain samples was 23 h in that study.16
In the NOBIS-II study, multi-marker (troponin-I, NT-proBNP (N-
terminal proBNP), CRP, D-dimer, and Lp-PLA2) testing was used in
patients with suspected ACS that presented to the emergency
department.17 The researchers investigated the role of the Lp-PLA2
level obtained during the acute stage in risk classiﬁcation of ACS
patients, and reported that Lp-PLA2 can be used for risk stratiﬁca-
tion not only in chronic CHD patients but also in ACS patients. It was
also reported that samples were drawn from patients at the time of
presentation and 6 h and 12e24 h after presentation; however, the
time between the onset of symptoms and sample drawn was not
clariﬁed. Quantitative analysis in the study showed that the
threshold value was 210 mg.L1. It was considerable that the median
Lp-PLA2 value of the 429 patients in the study was 205 mg L1. In
literature, an Lp-PLA2 mass 235 ng mL1 is the suggested cut-off
for increased risk.18 So, in the NOBIS-II study, the signiﬁcant pro-
portion of patients in the acute stage had Lp-PLA2 levels lower than
this cut-off value. As there was no control group in the NOBIS-II
study, comparison could not be possible.
In the PROVE IT-TIMI 22 study, no correlation was observed
between the Lp-PLA2 level in blood samples obtained during theTable 4
The diagnostic value of Lp-PLA2 by reference to troponin I in ACS group.
AUC
SE
CI 95%
Lp-PLA2
Cut-off (nmol/ml/min)
Sens. %
CI 95%
Spec. %
CI 95%
0,798
0.056
0,688e0,907
37.7 76
62e86
72
60e82
ACS: Acute coronary syndrome, AUC: Area under curve, SE: Standard error, CI: Conﬁd
Likelihood ratio, AR: Accuracy rate.
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j.tjem.2016.10.001ﬁrst 10 days (median 7 days) post-ACS and an increased risk of
recurrent CV (cardiovascular) event.19 This situation raises the
question if the cause of this result is decreased Lp-PLA2 levels in the
early stage; as the researchers did not measure the Lp-PLA2 level at
presentation and since there was no placebo or control group they
did not know if the Lp-PLA2 level increased during the acute stage,
and they could not conclude if there was a return to the basal level.
Research performed as a sub-study of the FRISC II, GUSTO IV,
and SWISCH studies investigated the effect of the Lp-PLA2 levels on
mortality and the development of new ischemic events.20 Blood
samples were obtained at median 38 h (interquartile range
28e53 h) in the FRISC II study and at median 15 h (interquartile
range 9.4e20 h) in the GUSTO IV study. The Lp-PLA2 level was
higher in ACS patients (in both cohorts) than in the healthy control
group; however, there was not a correlation between the Lp-PLA2
level, and the risk of new CV events or mortality. The authors also
reported that the time from the onset of symptoms to sample
drawn (up to 84 h) was not correlated with the Lp-PLA2 levels.
In consideration of the present study's results, it can be
concluded that the Lp-PLA2 level signiﬁcantly decreases during the
early stage of ACS and AIS. Again, when the sample drawn periods
and the obtained Lp-PLA2 levels are taken into consideration, it
appears that the Lp-PLA2 levels decrease in hours after an acute
event, remain low for days, and thereafter return to the basal level;
however, this is merely supposition. The exact time of the decrease
in Lp-PLA2 level after acute event, duration of decreased level's
persistence and the exact time to return to the basal level are not
known. As such, when performing prognostic assessment or risk
stratiﬁcation, it may be crucial to know if a patient has recently
experienced any acute events. On the other hand, as stated above,
there is a small number of papers reporting that Lp-PLA2 levels doPPV %
CI 95%
NPV %
CI 95%
(þ)LR
CI 95%
()LR
CI 95%
AR %
CI 95%
71
59e81
77
63e87
2.73
1.55e4.74
0.34
0.17e0.63
74
61e84
ence interval, PPV: Positive predictive value, NPV: Negative predictive value, LR:
hospholipase-A2 activity and its diagnostic potential in patients with
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Measurement of Lp-PLA2mass versus activity, and differences in
measurement methods and patient populations, patients' basal li-
poprotein levels, medications used, and cut-off values may account
for the inconsistency of published results. Moreover, although
numerous theories have been suggested to explain the decrease in
Lp-PLA2 level the actual cause is yet to be discerned. Enlightening
these issues through further studies and reaching a certain stan-
dardization in the studies would eliminate this obscure.4.1. Limitations
As this was a preliminary study with limited ﬁnancial support,
the number of patients was quite low. No power analysis was
performed to determine the sample count of the groups. The
impact of current diseases and patient use of pharmacological
agents on the results has been ignored. The most important limi-
tation of our study is the difference between the control group and
study groups with regard to age and gender, despite the fact that
the control group participants were selected among other patients
who had presented to the emergency unit and consecutively
included in the study. Furthermore, we have no data on a possible
difference between Lp-pLA2 measurements according to age or
gender in our country. The mass of the Lp-PLA2 enzyme could not
be studied along with its activity; hence, we could not determine if
there was a correlation in between mass and activity. Lp-PLA2 ac-
tivity was measured only once and its change over time was not
assessed; therefore, we could not determine how long this low
level persisted. Finally, the relationship between the lipoprotein
level and Lp-PLA2 level was not investigated. 00LDL-C00 levels that
was unable to view relationship and correlation with it. Patients
with ACS and AISwere not evaluated separately with regard to their
etiology.5. Conclusions
In the present study, AUC values, statistical data obtained for Lp-
PLA2 measured in both the ACS and AIS groups show that the
diagnostic performance of Lp-PLA2 was sufﬁcient. Statistical results
for optimum cut-off points showed that Lp-PLA2 can be more
beneﬁcial in the patients with ACS. The sensitivity and speciﬁcity of
the optimal cut-off points were higher in the ACS group than in the
AIS group. Although it was found that the levels of TnI and CK-MB
were higher and the levels of Lp-LA2 were decreasing in the ACS
group when compared with the control group, the fact that there
was not any negative correlation made investigators think that
independent factors had effect on those biomarkers. This was also
true for CRP. In conclusion, a decrease in the acute stage Lp-PLA2
level in ACS and AIS patientsmay be used for diagnostic purposes in
the emergency departments.Funding
None declared.Please cite this article in press as: Kocak S, et al., Lipoprotein-associated p
acute coronary syndrome and acute ischemic stroke, Turkish Jo
j.tjem.2016.10.001Conﬂict of interest
None declared.References
1. Zalewski A, Nelson JJ, Hegg L, Macphee C. Lp-PLA2: a new kid on the block. Clin
Chem. 2006;52(9):1645e1650.
2. The Lp-PLA2 Studies Collaboration. Lipoprotein-associated phospholipase A2
and risk of coronary disease, stroke, and mortality: collaborative analysis of 32
prospective studies. Lancet. 2010;375(9725):1536e1544.
3. Macphee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA. Lipoprotein-
associated phospholipase A2, platelet activating factor acetylhydrolase, gen-
erates two bioactive products during the oxidation of low-density lipoprotein:
use of a novel inhibitor. Biochem J. 1999;338:479e487.
4. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F.
Association between lipoprotein-associated phospholipase A2 and cardiovas-
cular disease: a systematic review. Mayo Clin Proc. 2007;82(2):159e165.
5. Kara H, Akinci M, Degirmenci S, Bayir A, Ak A, Nayman A, et al. High-sensitivity
C-reactive protein, lipoprotein-related phospholipase A2, and acute ischemic
stroke. Neuropsychiatr Dis Treat. 2014 Aug 6;10:1451e1457.
6. Jabor B, Choi H, Ruel I, Haﬁane A, Mourad W, Genest J. Lipoprotein-associated
phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with
low-density lipoprotein cholesterol. Can J Cardiol. 2013 Dec;29(12):
1679e1686.
7. Pepys MB, Gideon MH. C-reactive protein: a critical update. J Clin Investig.
2003;111:1805e1811.
8. Asanoa K, Okamotoa S, Fukunagaa K, Shiomia T, Moria T, Iwataa M, et al.
Cellular source(s) of platelet-activating-factor acetylhydrolase activity in
plasma. Biochem Biophys Res Commun. 1999;261:511e514.
9. Svetlov SI, Howard KM, Debuysere MS, Olson MS. Secretory PAF-
acetylhydrolase of the rat hepatobiliary system: characterization and partial
puriﬁcation. Am J Physiol Gastrointest Liver Physiol. 1998;274:891e900.
10. De Gennaro L, Brunetti ND, Cuculo A, Pellegrino PL, Izzo P, Roma F, et al.
Increased troponin levels in nonischemic cardiac conditions and noncardiac
diseases. J Interv Cardiol. 2008 Apr;21(2):129e139. http://dx.doi.org/10.1111/
j.1540-8183.2007.00336.x.
11. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third
universal deﬁnition of myocardial infarction. Eur Heart J. Oct 2012;33:
2551e2567. http://dx.doi.org/10.1093/eurheartj/ehs184.
12. Zalewski A, Macphee CH. Role of lipoprotein-associated phospholipase A2 in
atherosclerosis: biology, epidemiology, and possible therapeutic target. Arte-
rioscler Thromb Vasc Biol. 2005;25:923e931.
13. Stephens CJ, Graham RM, Sturm MJ, Richardson M, Taylor RR. Variation in
plasma platelet-activating factor degradation and serum lipids after acute
myocardial infarction. Coron Artery Dis. 1993 Feb;4(2):187e193.
14. Serebruany VL, Gurbel PA, Murugesan SR, Lowry DR, Sturm E, Svetlov SI.
Depressed plasma platelet-activating factor acetylhydrolase in patients pre-
senting with acute myocardial infarction. Cardiology. 1998;90:127e130.
15. Elkind MSV, Leon V, Moon YP, Paik MC, Sacco RL. High-sensitivity C-Reactive
protein and lipoprotein-associated phospholipase A2 stability before and after
stroke and myocardial infarction. Stroke. 2009;40:3233e3237.
16. Tai W, Garcia M, Mlynash M, Kemp S, Albers GW, Olivot JM. Lipoprotein
phospholipase A2 mass and activity are not associated with the diagnosis of
acute brain ischemia. Cerebrovasc Dis. 2014 Nov 21;38(5):324e327.
17. M€ockel M, Müller R, Vollert JO, Müller C, Danne O, Gareis R, et al. Lipoprotein-
associated phospholipase A2 for early risk stratiﬁcation in patients with sus-
pected acute coronary syndrome: a multi-marker approach the north Wuert-
temberg and Berlin infarction study-II (NOBIS-II). Clin Res Cardiol. 2007;96:
604e612.
18. Lanman RB, Wolfert RL, Fleming JK, Jaffe AS, Roberts WL, Warnick GR, et al.
Lipoprotein-associated phospholipase A2: review and recommendation of a
clinical cut point for adults. Prev Cardiol. 2006;9:138e143.
19. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP,
et al. Lipoprotein-associated phospholipase A2 and its association with car-
diovascular outcomes in patients with acute coronary syndromes in the PROVE
IT-TIMI 22 (pravastatin or atorvastatin evaluation and infection therapye-
thrombolysis in myocardial infarction. Trial Circ. 2006;113:1745e1752.
20. Oldgren J, James SK, Siegbahn A, Wallentin L. Lipoprotein-associated phos-
pholipase A2 does not predict mortality or new ischaemic events in acute
coronary syndrome patients. Eur Heart J. 2007;28:699e704.hospholipase-A2 activity and its diagnostic potential in patients with
urnal of Emergency Medicine (2016), http://dx.doi.org/10.1016/
